Company Name: |
Beijing Comparison Pharmaceutical Technology Co., Ltd
|
Tel: |
010-52878169 15701683040 |
Email: |
sales@bjcomparison.com |
Products Intro: |
Product Name:N-[2-hydroxy-5-[(1RS)-1-hydroxy-2-[[(1SR)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-formamide CAS:532414-36-1 Purity:≥95% Package:100mg
|
Company Name: |
ChemStrong Scientific Co.,Ltd
|
Tel: |
0755-0755-66853366 13670046396 |
Email: |
sales@chem-strong.com |
Products Intro: |
Product Name:Formoterol EP Impurity I CAS:532414-36-1 Purity:95% HPLC Package:10mg;25mg;50mg;100mg
|
|
| Formoterol Fumarate Dihydrate EP Impurity I Basic information |
Product Name: | Formoterol Fumarate Dihydrate EP Impurity I | Synonyms: | Formoterol impurity 9/Formoterol EP Impurity I/rel-N-(2-Hydroxy-5-((R)-1-hydroxy-2-(((S)-1-(4-methoxyphenyl)propan-2-yl)amino)ethyl)phenyl)formamide;Formoterol Impurity 9(Formoterol EP Impurity I);anti-rac-Formoterol;Formoterol Fumarate Impurity Ⅰ:rel-(R,S)-Formoterol;rel-N-[2-Hydroxy-5-[(1R)-1-hydroxy-2-[[(1S)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide;Arformoterol Impurity 22;N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2S)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;N-(2-hydroxy-5-((R)-1-hydroxy-2-(((S)-1-(4-methoxyphenyl)propan-2-yl)amino)ethyl)phenyl)formamide | CAS: | 532414-36-1 | MF: | C19H24N2O4 | MW: | 344.4 | EINECS: | | Product Categories: | | Mol File: | 532414-36-1.mol | |
| Formoterol Fumarate Dihydrate EP Impurity I Chemical Properties |
Boiling point | 603.2±55.0 °C(Predicted) | density | 1.233±0.06 g/cm3(Predicted) | solubility | DMSO (Slightly), Methanol (Slightly) | pka | 8.95±0.50(Predicted) | form | Solid | color | White to Off-White |
| Formoterol Fumarate Dihydrate EP Impurity I Usage And Synthesis |
Uses | rel-(R,S)-Formoterol is a stereoisomer of Formoterol (F693395). Formoterol is a long-acting inhaled beta-2 agonist (bronchodilator) that is used to treat patients with COPD and asthma. |
| Formoterol Fumarate Dihydrate EP Impurity I Preparation Products And Raw materials |
|